nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

被引：0
作者：
Mustapha Tehfe
Scot Dowden
Hagen Kennecke
Robert El-Maraghi
Bernard Lesperance
Felix Couture
Richard Letourneau
Helen Liu
Alfredo Romano
机构：
[1] Centre hospitalier de l’université de Montréal (CHUM),
[2] Tom Baker Cancer Centre,undefined
[3] British Columbia Cancer Agency,undefined
[4] Royal Victoria Regional Health Centre,undefined
[5] Hôpital du Sacré-Coeur de Montreal,undefined
[6] Centre hospitalier universitaire de Québec (CHUQ),undefined
[7] Hôtel-Dieu de Quebec,undefined
[8] CHUM,undefined
[9] Celgene Corporation,undefined
来源：
Advances in Therapy | 2016年 / 33卷
关键词：
Canada; Gemcitabine; Metastatic pancreatic cancer; MPACT; -Paclitaxel; Oncology; Subgroup analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：747 / 759
页数：12
相关论文
共 34 条
  • [1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403
  • [2] Steliarova-Foucher E(2015)Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Drug Des Devel Ther 9 3529-3545
  • [3] Lortet-Tieulent J(2014)The current state of pancreatic cancer in Canada: incidence, mortality, and surgical therapy Pancreas 43 879-885
  • [4] Chiorean EG(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
  • [5] Coveler AL(2015)Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer Oncologist 20 143-150
  • [6] Hurton S(2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205-216
  • [7] MacDonald F(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-181
  • [8] Porter G(2016)Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy Int J Clin Oncol 21 118-125
  • [9] Walsh M(2015)A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy J Cancer Res Clin Oncol 141 1653-1660
  • [10] Molinari M(2015)Predicting survival after irradiation of metastases from pancreatic cancer Anticancer Res 35 4105-4108
1234